On this page

Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension

neomycin and polymyxin B sulfates and hydrocortisone otic · Suspension

Prescription NDA TE AT RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension
Generic name
neomycin and polymyxin B sulfates and hydrocortisone otic
Dosage form
Suspension
Route
Auricular (Otic)
Marketing category
NDA AUTHORIZED GENERIC · NDA AG
Labeler
Rising Pharma Holdings, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
3
NDC product codes
3
Packages
3
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Hydrocortisone 10 mg/mL 604449 View
Neomycin Sulfate 3.5 mg/mL 204602 View
Polymyxin B Sulfate 10000 [USP'U]/mL 204602 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Suspension
Route of administration
Auricular (Otic)
Presentations
6

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Aminoglycoside Antibacterial [EPC] EPC All 66 members
Aminoglycosides [CS] CS All 66 members
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members
Polymyxin-class Antibacterial [EPC] EPC All 55 members
Polymyxins [CS] CS All 55 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
060613
Application type
NDA · New Drug Application
Approval date
May 25, 1975
Sponsor
CASPER PHARMA LLC
Products on application
1
Submissions recorded
9
Products approved under application 060613.
Product Trade name Form Strength Ingredient Status TE Flags
060613-001 CASPORYN HC SUSPENSION/DROPS HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE Prescription AT RLD

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
Yes
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 060613.
Type No. Action Status Date Review
Supplement 14 Manufacturing (CMC) Approved March 15, 2019 Standard
Supplement 13 Labeling Approved December 19, 2017 Standard
Supplement 9 Labeling Approved August 10, 2000 —
Supplement 8 Labeling Approved August 10, 2000 —
Supplement 10 Manufacturing (CMC) Approved July 23, 1999 —
Supplement 7 Manufacturing (CMC) Approved February 14, 1995 —
Supplement 5 Labeling Approved March 30, 1993 —
Supplement 4 Labeling Approved February 4, 1988 —
Original application 1 Approved May 25, 1975 —

Review documents

  • 0 · Supplement · September 23, 2024
  • 0 · Supplement · September 23, 2024
  • 0 · Supplement · December 21, 2017

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260804). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260804 HUMAN PRESCRIPTION DRUG · 20230123

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Therapy with this product should be limited to 10 consecutive days. The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. For adults, 4 drops of the suspension should be instilled into the affected ear 3 or 4 times daily. For children, 3 drops are suggested because of the smaller capacity of the ear canal. The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear. If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the suspension. This wick should be kept moist by adding further suspension every 4 hours. The wick should be replaced at least once every 24 hours. SHAKE WELL BEFORE USING.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS This product is contraindicated in those individuals who have shown hypersensitivity to any of its components, and in herpes simplex, vaccinia, and varicella infections.

WARNINGS Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days (see PRECAUTIONS-General ). Patients being treated with eardrops containing neomycin should be under close clinical observation. Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension should not be used in any patient with a perforated tympanic membrane. Discontinue promptly if sensitization or irritation occurs. Neomycin sulfate may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known. When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin containing applications should be avoided for the patient thereafter.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS ). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear. To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharmaceuticals, Inc. at 1-866-562-4597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Description

openFDA Drug Labeling

DESCRIPTION Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use. Each mL contains: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, and hydrocortisone 10 mg (1%). The vehicle contains thimerosal 0.01% (added as a preservative) and the inactive ingredients cetyl alcohol, propylene glycol, polysorbate 80, and Water for Injection. Sulfuric acid may be added to adjust pH. Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 mcg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are: Polymyxin B sulfate is the sulfate salt of polymyxin B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are: Hydrocortisone, 11β, 17, 21-trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. Its structural formula is: struct1 struct2 struct3

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED 10 mL bottle (NDC 68788-7787-1). Store at 15° to 25°C (59° to 77°F). Rx only KEEP OUT OF REACH OF CHILDREN. Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Code No.: TS/DRUGS/13/2010 Made in India PIA44801-03 Revised: 05/2024 P1537072

Adverse event reports

Source: openFDA FAERS
123,956
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: HYDROCORTISONE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-6336-0 50090-6336 A-S Medication Solutions 1 BOTTLE in 1 CARTON (50090-6336-0) / 10 mL in 1 BOTTLE January 18, 2023
68788-7787-1 68788-7787 Preferred Pharmaceuticals, Inc. 1 BOTTLE in 1 CARTON (68788-7787-1) / 10 mL in 1 BOTTLE October 21, 2020
64980-448-01 64980-448 Rising Pharma Holdings, Inc. 1 BOTTLE in 1 CARTON (64980-448-01) / 10 mL in 1 BOTTLE March 15, 2019
50090-6336 50090-6336 A-S Medication Solutions — March 15, 2019
68788-7787 68788-7787 Preferred Pharmaceuticals, Inc. — October 21, 2020
64980-448 64980-448 Rising Pharma Holdings, Inc. — March 15, 2019

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.